BioSpace News Archive

PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”), a biomedical company focused on meeting significant unmet needs for women worldwide.

Biocare Medical, a leading provider in the immunohistochemistry sector, introduces their newest innovation: ARC (Antigen Retrieval Chamber).

INmune Bio, Inc. has received acceptance of a Clinical Trial Application (CTA) under EU Clinical Trials Regulation to initiate a Phase II trial in Early Alzheimer’s Disease (AD) with XPro™ in Poland.

Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced the successful completion of a significant paid-in capital increase of $150 million.

MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company” or “MustGrow”) is pleased to announce receipt of the Washington State Department of Agriculture Fertilizer Registration Certificate for its mustard plant-based TerraSanteTM crop fertilizer and soil amendment product.

Findings from a second joint study by Genzeva, a leading molecular genetic laboratory that performs whole genome and clinical exome sequencing for clinical diagnostics and research, and tech innovator RYLTI again illustrate the potential of their breakthrough process to accelerate discovery in genomic research.

QIAGEN announced the expansion of its sample technologies portfolio with the introduction of two new products aimed at supporting researchers in managing diverse materials such as bone, tissue and soil samples.

Regeneron Pharmaceuticals, Inc. will webcast management participation.

AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use Disorder

Mammogen, a leader in women’s health and bellwether subsidiary of early detection parent company IVBH, has announced the successful completion of Clinical Laboratory Improvement Amendments (CLIA) validation for its pioneering plasma-based clinical assay, genTRU-breast, a test designed to detect the earliest stages of breast cancer.